Mithra Pharmaceuticals SA (OTCPK:MITPF)

$ 6.75 0 (0%) Market Cap: 15.66 Mil Enterprise Value: 215.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Half Year 2023 Mithra Pharmaceuticals SA Earnings Call Transcript
Sep 26, 2023

$6.75

Earnings
Q4 2022 Mithra Pharmaceuticals SA Earnings Call Transcript
Mar 07, 2023

$6.75

Earnings
Mithra Pharmaceuticals SA and Richter Gedeon Vegyeszeti Gyar Nyrt to Discuss Partnership for the Commercialisation of Donesta Presentation Transcript
Dec 20, 2022
Q2 2022 Mithra Pharmaceuticals SA Earnings Call Transcript
Sep 23, 2022

$6.75

Earnings
Full Year 2021 Mithra Pharmaceuticals SA Earnings Call Transcript
Mar 08, 2022

$22.7

Earnings
Mithra Pharmaceuticals SA to Discuss Donesta Top-Line Results Call Transcript
Jan 14, 2022
Half Year 2021 Mithra Pharmaceuticals SA Earnings Call Transcript
Sep 24, 2021

$23.9

Earnings
Full Year 2020 Mithra Pharmaceuticals SA Earnings Call Transcript
Mar 09, 2021

$23.91

Earnings
Half Year 2020 Mithra Pharmaceuticals SA Earnings Call Transcript
Sep 24, 2020

$24.23

Earnings
Mithra Pharmaceuticals SA at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020

Mithra Pharmaceuticals SA to Discuss Donesta Top-Line Results Call Transcript

Jan 14, 2022 / 08:00AM GMT

Release Date Price: $23.9

Transcript

Operator

Hello, and welcome to the Donesta top line efficacy results Phase III. My name is Courtney, and I'll be your coordinator for today's event. Please note that this call is being recorded.

(Operator Instructions)

And I will now hand you over to your host, Benoit Mathieu, Group Investor Relations Manager, to begin today's conference. Thank you.

Benoit Mathieu

Mithra Pharmaceuticals SA - Group IR Manager

Good morning, ladies and gentlemen. Welcome to all of you. And as you have seen in our press release this morning, we have decided to organize this webcast in order to present in more details to Donesta top line efficacy results. My name is Benoit Mathieu, Investor Relations Officer, and I'm joining the room by our CEO, Leon Van Rompay; Graham Dixon, our Chief Scientific Officer; and Jean-Michel Foidart, our Chief Business Officer.

This webcast is recorded and will be accessible later today on Mithra's website. I would like to remind you that this webcast is covered by the disclaimer on Slide 2 of this presentation. The format of today

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.